Results 61 to 70 of about 10,352,886 (166)

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Psychostimulants and movement disorders.

Frontiers in Neurology, 2015
Psychostimulants are a diverse group of substances with their main psychomotor effects resembling those of amphetamine, methamphetamine, cocaine or cathinone.
Andres eAsser, Pille eTaba
doaj   +1 more source

Comparing COVID-19-related Morbidity and Mortality Between Patients With and Without Substance Use Disorders: A Retrospective Cohort Study

Substance Abuse: Research and Treatment, 2023
Objectives: People with substance use disorders (SUD) are suggested to have higher risk of hospitalization, intubation, or death from coronavirus disease 2019 (COVID-19), although data are mixed. Little is known about other COVID-19-related complications
Angela McLaughlin, Rebecca Burns, Morgan Ryan, Wafaa Abbasi, Leah Harvey, Jacqueline Hicks, Pranay Sinha, Sabrina A Assoumou   +7 more
doaj   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Treatment of Attention Deficit/Hyperactivity Disorder With Amphetamine: Short-Term Effects on Family Interaction. [PDF]

, 2008
Objective: This research seeks to study the impact on family function after 3 months of treatment with amphetamine. Method: A total of 43 children, 6 to 11 years of age, with ADHD were treated with amphetamine for 3 months.
Thernlund, Gunilla,, Svedin, Carl Göran, Eidevall, Lena, Gustafsson, Peik, Eidevall, Lena,, Hansson, Kjell, Thernlund, Gunilla, Lund University., Gustafsson, Peik,, Hansson, Kjell,, Svedin, Carl Göran,   +10 more
core   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

The Dopamine Allosteric Agent, PAOPA, Demonstrates Therapeutic Potential in the Phencyclidine NMDA Pre-clinical Rat Model of Schizophrenia

Frontiers in Behavioral Neuroscience, 2018
PAOPA, a potent analog of prolyl-leucyl-glycinamide, has shown therapeutic potential at the preclinical stage for dopaminergic related illnesses, including animal models of schizophrenia, Parkinson’s disease and haloperidol-induced extrapyramidal ...
Ritesh P. Daya, Jayant Bhandari, Sharnpreet K. Kooner, Joella Ho, Christopher D. Rowley, Nicholas A. Bock, Troy Farncombe, Ram K. Mishra   +7 more
doaj   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Defining a role for the peduncolopontine tegmental nucleus in striatal outflow [PDF]

, 2012
The pedunculopontine tegmental nucleus (PPTg) lies within the pontomesencephalon and contains cholinergic and non-cholinergic neurones. It has extensive afferent and efferent connections throughout the brain.
Allen, Laura F.
core   +1 more source

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien, Lisa‐Marie Greenwood, Arush Honnedevasthana Arun, Isabella Goodwin, Anastasia Paloubis, Tribikram Thapa Rana, Marianna Quinones Valera, Eugene McTavish, Gabrielle Abbott, Suraya Dunsford, Antonio Verdejo‐Garcia, Jessica Ramamurthy, Mark M. Schira, Nadia Solowij, Chao Suo, Valentina Lorenzetti   +15 more
wiley   +1 more source